Prostate Cancer
Conditions
Keywords
Tinengotinib (TT-00420), Androgen Receptor Signaling Inhibitors (ARSIs), TIP Study: Tinengotinib In Prostate Cancer, Prostate Cancer Clinical Trials Consortium, LLC (PCCTC), 24-103
Brief summary
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
DRUGTinengotinib
Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)
DRUGEnzalutamide
Enzalutamide 160 mg PO QD
Sponsors
Memorial Sloan Kettering Cancer Center
TransThera Sciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
In the Phase 1b portion of the study, participants will be enrolled sequentially in cohorts of 3 for each studied combination. The recommended Phase II dose (RP2D) of each combination will be estimated separately based on the de-escalation rules.
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants ≥ 18 years old, with signed informed consent * Histologically confirmed carcinoma of the prostate (neuroendocrine differentiation is allowed, but pure small cell carcinoma is not permitted) * Metastatic disease documented by at least 2 bone lesions on whole body radionuclide bone scan, or soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI). Note: Metastatic disease seen only on PET imaging does not qualify. * Current ongoing therapy and observed tolerance with full standard dose of abiraterone acetate (1000 mg QD) or enzalutamide (160 mg QD) at the time of study entry. Enzalutamide or abiraterone acetate must have been started at least 90 days before screening assessments. An interruption of dosing of a maximum of 30 days is permitted prior to resuming the agent. Please note: Patients who are on a reduced dose or are intolerant of abiraterone acetate or enzalutamide at screening will not be eligible for study participation. * Progressive disease on enzalutamide or abiraterone acetate documented by PCWG3 criteria for study entry. Progressive disease is defined as at least one of the following: 1. PSA progression defined as a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination, reaching a minimum PSA value of 1.0 ng/mL. 2. Nodal or visceral progression as defined by PCWG3-modified RECIST 1.1 3. Appearance of 2 or more new lesions on a bone scan * At least one of the following at study entry: 1. RECIST 1.1 measurable disease at baseline; i.e., soft tissue tumor lesions or pathologically enlarged lymph nodes that can be accurately measured in at least one dimension OR 2. a PSA of 2.0 ng/mL or above * Participants must be medically or surgically castrated with ongoing androgen deprivation therapy (ADT) for ≥90 days or have documented history of bilateral orchiectomy. * ECOG 0 - 2 * Adequate organ function confirmed at screening, as evidenced by: * Absolute neutrophil count ≥ 1.5 × 10\^9 /L * Hemoglobin ≥ 9 g/dL * Platelets ≥ 75 × 10\^9 /L * Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5.0 × ULN if liver metastases are present * Total bilirubin ≤ 1.5 × ULN; or \< 2.5 × ULN if Gilbert syndrome or disease involving liver * Creatinine clearance \>30 mL/min (Cockcroft-Gault formula) * Adequate blood coagulation function as evidence by an international normalized ratio (INR) ≤ 1.5 unless participant is on anticoagulants * Tumor biopsy during screening is required if safe and feasible. If archival tissue is available from a previous biopsy performed within 90 days of screening assessments, a repeat screening biopsy is not required even if safe and feasible. If neither option is possible, archival tissue from any timepoint should be requested, if available.
Exclusion criteria
* The presence of any of the following criteria excludes a patient from participating in the study: * Pure small cell carcinoma * Previous exposure to multi-TKI therapies. * Uncontrolled hypertension (persistent systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg) or known coronary artery disease with angina. Patients with known hypertension must be on antihypertensive medication with BPs generally \<140/90 to be eligible. * History of congestive heart failure of Class II-IV New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months of study entry, or prolongation of QTc interval to \>480 msec using Fridericia formula (QTcF) at screening (except for participants with pacemakers, where there is no QTc cutoff). * Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessments. * Symptomatic and/or untreated CNS metastases. * Pre-existing duodenal stent or any gastrointestinal disorder or defect which would interfere with absorption of study medication, as determined by the Investigator. * Persistent requirement for corticosteroids at equivalent of \>10 mg QD prednisone within 14 days before study treatment start. * Other anticancer therapies within 3 weeks of study treatment start, or within 5 half-lives of study treatment start for non-cytotoxic oral agents, whichever is shorter; with the exception of androgen deprivation therapy, enzalutamide, or abiraterone acetate which should be continued through study treatment. * Palliative radiation within 2 weeks of study treatment start.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RP2D | From the start of study treatment through the DLT window (28 days) | Evaluate DLT occurrence to confirm safety and RP2D |
| Objective Response Rate (ORR) | up to 6months | by local investigator's assessment per PCWG3-modified RECIST v1.1 in participants with baseline measurable disease OR rate of PSA decline of ≥ 50% from baseline in patients with a baseline PSA of 2.0 ng/mL or above |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Radiographic Response (phase II) | From start of study treatment until 6 months post study treatment start | Rate of radiographic response by local investigator's assessment per PCWG3-modified RECIST v1.1 in participants with baseline measurable disease |
Countries
United States
Contacts
CONTACTWassim Abida, MD, PhD
CONTACTMichael Morris, MD
PRINCIPAL_INVESTIGATORWassim Abida, MD, PhD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed